Cisplatin, fluorouracil, interferon-alpha, and radiation as adjuvant therapy for resected pancreatic cancer: is there a future for this regimen and/or should we change our approach to research and treatment of patients with pancreatic cancer? Ann Surg 2008 Aug;248(2):152-3
Date
07/25/2008Pubmed ID
18650622DOI
10.1097/SLA.0b013e3181820d35Scopus ID
2-s2.0-49849088623 (requires institutional sign-in at Scopus site) 4 CitationsAuthor List
Pisters PW, Evans DBAuthor
Douglas B. Evans MD Chair, Professor in the Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antineoplastic Combined Chemotherapy ProtocolsChemotherapy, Adjuvant
Cisplatin
Combined Modality Therapy
Female
Fluorouracil
Forecasting
Humans
Interferon-alpha
Male
Neoplasm Staging
Pancreatectomy
Pancreatic Neoplasms
Prognosis
Radiotherapy Dosage
Radiotherapy, Adjuvant
Research
Risk Assessment
Sensitivity and Specificity
Survival Analysis